MYGN Q2 2018 Earnings — Myriad Genetics, Inc. Revenue & Financial Results | Market Cap Arena

MYGNMyriad Genetics, Inc.

$454M

Q2 2018 Earnings

Healthcare Medical - Diagnostics & Research

Income Statement

Revenue

$201M+0.2% YoY

Gross Profit

$155M77.3% margin

Operating Income

$16M7.9% margin

Net Income

$13M6.5% margin

EPS (Diluted)

$0.18

QoQ Revenue Growth

+3.8%

Cash Flow

Operating Cash Flow

$48M

Free Cash Flow

$46M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$1.2B

Total Liabilities

$209M

Stockholders' Equity

$965M

Cash & Equivalents

$111M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$201M	$201M	+0.2%
Gross Profit	$155M	$158M	-1.8%
Operating Income	$16M	$17M	-7.0%
Net Income	$13M	$13M	+1.6%

Revenue Segments

Molecular Diagnostic Testing

$188M93%

Pharmaceutical And Clinical Services

$13M7%